Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-08-Speech-3-083"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-08"^^xsd:date2
dcterms:Is Part Of	lp_eu:Ongoing negotiations on the Anti-Counterfeiting Trade Agreement (ACTA) (debate)2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20100908.5.3-083"2
lpv:hasSubsequent	lp_eu:2010-09-08-Speech-3-0842
lpv:speaker	lp:Niccolò Rinaldi2
lpv:spokenAs	substitute; DROI (2009-07-16--2012-01-18)3,3 member; Delegation to the EU-Kazakhstan, EU-Kyrgyzstan and EU-Uzbekistan Parliamentary Cooperation Committees, and for relations with Tajikistan, Turkmenistan and Mongolia (2009-09-16--2014-06-30)3,3 member; INTA (2009-07-16--2012-01-18)3,3 member; Delegation for relations with the countries of South Asia (2009-09-16--2014-06-30)3,3 member; Delegation for relations with the Palestinian Legislative Council (2009-09-16--2014-06-30)3,3 unknown; Italia dei Valori - Lista Di Pietro (2009-07-14--2014-04-14)3,3 substitute; DEVE (2009-07-16--2012-01-18)3,3 vice-chair; ALDE (2009-07-14--2012-01-26)3,3 substitute; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3,3
lpv:translated text	"Mr President, Commissioner, ladies and gentlemen, ‘ ’ – ‘the play is over, applaud!’ – as Roman actors used to say at the end of a performance. The play is over and perhaps we are on the eve of its conclusion, although it may not yet be time to applaud. During this debate, we have been given important reassurances by Mr De Gucht, but we know that 64% of counterfeit goods come from China, which is not a party to the Anti-Counterfeiting Trade Agreement (ACTA). We will therefore need to assess whether it is all worthwhile – in other words, whether we ought to sign the agreement if it does not bring any real benefits, as the Commissioner concluded. There are not many causes of concern remaining, but they are significant. A lot has been said about the Internet, and we appreciate the Commission’s efforts, but we remain vigilant. As regards access to medicines, I repeat what has already been demanded by other Members: there can be no lumping together of counterfeit medicines on the one hand and generic medicines on the other. It is vital to allow access to medicines at competitive prices, which are crucial for patients in developing countries. The question I should like to ask is whether the Doha declaration on the TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement and public health will be included at least in the preamble of the ACTA text. Lastly, as regards geographical indications, we find ourselves in a potentially paradoxical situation, because registered trademarks that might violate geographical indications would enjoy greater protection than the geographical indications themselves. Here, too, TRIPS provides a sounder basis in many respects, and we therefore call for vigilance and a firm stance."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph